Serotonin receptors: Their key role in drugs to treat schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 7, 2003, Pages 1159-1172

  Meltzer, Herbert Y ^a   Li, Zhu ^a   Kaneda, Yasuhiro ^a   Ichikawa, Junji ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drugs; Dopamine; Extrapyramidal syndrome; Negative signs; Serotonin receptors

Indexed keywords

AMPEROZIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR; SULPIRIDE;

ARTICLE; BRAIN REGION; DRUG RECEPTOR BINDING; DRUG RESPONSE; HUMAN; MAJOR DEPRESSION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEROTONIN RELEASE;

EID: 0345258416     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.09.010     Document Type: Article

References (180)

1. Abi-Saab W.M., Bubser M., Roth R.H., Deutch A.Y. 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology. 20:1999;92-96.
2. Altar C.A., Wasley A.M., Neale R.F., Stone G.A. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. 16:1986;517-525.
3. Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathe J.M., Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;374-385.
4. Anonymous Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J. Clin. Psychiatry. 59(Suppl. 12):1998;41-45.
5. Antoniou K., Bekris S., Saranti M., Stathis P., Rimikis M., Papadopoulou-Daifoti Z. The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus. Eur. Neuropsychopharmacol. 10:2000;315-524.
6. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 40:1991;399-412.
7. Arnsten A.F.T. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn. Sci. 2:1998;436-447.
8. 2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural Transm. 85:1991;19-29.
9. Arranz M., Collier D., Sodhi M., Ball D., Roberts G., Price J., Sham P., Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 346:1995;281-282.
10. 1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur. J. Pharmacol. 334:1997;141-147.
11. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J. Psychopharmacol. 15:2001;37-46.
12. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
13. Bentley J.C., Bourson A., Boess F.G., Fone K.C., Marsden C.A., Petit N., Sleight A.J. Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br. J. Pharmacology. 126:1999;1537-1542.
14. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse. 1:1987;470-480.
15. 2A/2C receptor antagonist, potentiates haloperidol-induced DA release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 27:2002;430-441.
16. 6 receptors in nigro-striatal function in rodents. Br. J. Pharmacol. 125:1998;1562-1566.
17. 6 receptors as emerging targets for drug discovery. Annu. Rev. Pharmacol. Toxicol. 40:2000;319-334.
18. Burki H.R., Eichenberger E., Sayers A.C., White T.G. Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal. Pharmakopsychiatr. Neuro-Psychopharmakol. 8:1975;115-121.
19. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-555.
20. 2 receptors. J. Pharmacol. Exp. Ther. 302:2002;381-389.
21. Burt D.R., Enna S.J., Creese I., Snyder S.H. Dopamine receptor binding in the corpus striatum of mammalian brain. Proc. Natl. Acad. Sci. USA. 72:1975;4655-4659.
22. Bymaster F.P., Felder C.C. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol. Psychiatry. 7(Suppl. 1):2002;S57-S63.
23. Cai X., Flores-Hernandez J., Feng J., Yan Z. Activity-dependent bidirectional regulation of GABA(A) receptor channels by the 5-HT(4) receptor-mediated signalling in rat prefrontal cortical pyramidal neurons. J. Physiol. 540:2002;743-759.
24. 2+/calmodulin- dependent kinase II in prefrontal cortical pyramidal neurons. J. Biol. Chem. 277:2002;36553-36562.
25. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am. J. Psychiatry. 135:1978;165-173.
26. Carlsson A., Lindquist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20:1963;140-144.
27. Celada P., Puig M.V., Casanovas J.M., Guillazo G., Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors. J. Neurosci. 21:2001;9917-9929.
28. Chaki S., Funakoshi T., Yoshikawa R., Okuyama S., Kumagai T., Nakazato A., Nagamine M., Tomisawa K. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats. Neuropharmacology. 38(8):1999;1185-1194.
29. Chivers J.K., Gommeren W., Leysen J.E., Jenner P., Marsden C.D. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J. Pharm. Pharmacol. 40:1988;415-421.
30. 1B receptors. J. Pharmacol. Exp. Ther. 277:1996;823-830.
31. Cozzi N.V., Nichols D.E. 5-HT2A receptor antagonists inhibit potassium-stimulated gamma-aminobutyric acid release in rat frontal cortex. Eur. J. Pharmacol. 309:1996;25-31.
32. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
33. Davies M.F., Deisz R.A., Prince D.A., Peroutka S.J. Two distinct effects of 5-hydroxytryptamine on single cortical neurons. Brain Res. 423(1-2):1987;347-352.
34. 6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 25:2001;662-668.
35. De Vane C.L. Differential pharmacology of newer antidepressants. J. Clin. Psychiatry. 59(Suppl. 20):1998;85-93.
36. 2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology. 37:1998;65-72.
37. 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology. 38:1999;1195-1205.
38. 2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br. J. Psychiatry. 163:1993;451-455.
39. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. USA. 98:2001;6917-6922.
40. 7 receptors in the suprachiasmatic nucleus. J. Neurosci. 21:2001;5351-5357.
41. Fadel J., Sarter M., Bruno J.P. Basal forebrain glutamatergic modulation of cortical acetylcholine release. Synapse. 39:2001;201-212.
42. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry. 1988;71-76.
43. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
44. 2 receptor binding in risperidone-treated schizophrenic patients. J. Clin. Psychopharmacol. 15:1995;19S-23S.
45. Feng J., Cai X., Zhao J., Yan Z. Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J. Neurosci. 21:2001;6502-6511.
46. 6 receptor mRNA levels in rat brain. Schizophr. Res. 38:1999;7-12.
47. Garraway S.M., Hochman S. Pharmacological characterization of serotonin receptor subtypes modulating primary afferent input to deep dorsal horn neurons in the neonatal rat. Br. J. Pharmacol. 132:2001;1789-1798.
48. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology. 135:1998;119-126.
49. 1 receptor antagonist. Lancet. 337:1991;854-855.
50. Gill H.S., DeVane C.L., Risch S.C. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J. Clin. Psychopharmacol. 17:1997;377-389.
51. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse. 36:2000;205-221.
52. Green M.F., Marshall B.D., Wirshing W.C., Ames D., Marder S.R., McGurk S., Kern R.S., Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry. 154:1997;799-804.
53. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 34:1993;702-712.
54. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry. 158:2001;176-184.
55. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science. 286(5437):1999;105-107.
56. Hirose A., Sasa M., Akaike A., Takaori S. Inhibition of hippocampal CA1 neurons by 5-hydroxytryptamine, derived from the dorsal raphe nucleus and the 5-hydroxytryptamine1A agonist SM-3997. Neuropharmacology. 29:1990;93-101.
57. Hoyer D., Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res. 376:1986;97-107.
58. 1A receptor agonist, potentiated S(-) sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J. Pharmacol. Exp. Ther. 291:1999;1227-1232.
59. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 351:1998;163-171.
60. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531.
61. 2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res. 907:2001;151-155.
62. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 26:2002;325-339.
63. 2A receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res. 939:2002;34-42.
64. 1A receptor agonism. Brain Res. 956:2002;349-357.
65. Jakab R.L., Goldman-Rakic P.S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Nat. Acad. Sciences USA. 95:1998;735-740.
66. 1A receptor. Eur. J. Pharmacol. 441:2002;137-140.
67. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry. 63:2002;763-771.
68. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry. 153:1996;466-476.
69. Kapur S., Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 25:2000;161-166.
70. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry. 158:2001;360-369.
71. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry. 155:1998;921-928.
72. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry. 156:1999;286-293.
73. Kapur S., McClelland R.A., VanderSpek S.C., Wadenberg M.L., Baker G., Nobrega J., Zipursky R.B., Seeman P. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. NeuroReport. 13:2002;831-835.
74. Kelland M.D., Chiodo L.A. Serotonergic modulation of midbrain dopamine systems. Ashby C.R. The modulation of dopaminergic neurotransmission by other neurotransmitters. 1996;87-122 CRC Press, New York.
75. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., Morita S. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274:1995;329-336.
76. Kramer M.S., Last B., Getson A., Reines S.A. The effects of a selective D4 Dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch. Gen. Psychiatry. 54:1997;567-572.
77. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1999;774-781.
78. Lapierre Y.D. Pharmacological therapy of dysthymia. Acta Psychiatr. Scand., Suppl. 383:1994;42-48.
79. Laruelle M., Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 13:1999;358-371.
80. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 20:1999;612-627.
81. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry. 55(Suppl. B):1994;82-87.
82. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 37:1999;1-11.
83. Lieberman J.A. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br. J. Psychiatr., Suppl. 22:1993;7-18.
84. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947:2002;157-165.
85. Lucas G., Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 74:2000;693-701.
86. Marcus M.M., Malmerfelt A., Nyberg S., Svensson T.H. Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses. Eur. Neuropsychopharmacol. 12:2002;379-386.
87. Martin-Ruiz R., Puig M.V., Celada P., Shapiro D.A., Roth B.L., Mengod G., Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J. Neurosci. 21:2001;9856-9866.
88. Masellis M., Basile V.S., Meltzer H.Y., Lieberman J.A., Sevy S., Macciardi F.M., Cola P., Howard A., Badri F., Nöthen M.M., Kalow W., Kennedy J.L. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 19(2):1998;123-132.
89. Masellis M., Basile V.S., Meltzer H.Y., Lieberman J.A., Sevy S., Goldman D.A., Hamblin M.W., Macciardi F.M., Kennedy J.L. Lack of association between the T→C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr. Res. 47:2001;49-58.
90. Materi L.M., Semba K. Inhibition of synaptically evoked cortical acetylcholine release by intracortical glutamate: involvement of GABAergic neurons. Eur. J. Neurosci. 14:2001;38-46.
91. 2 receptor density in rat cerebral cortex. Life Sci. 45:1989;1397-1406.
92. Matsuyama S., Nei K., Tanaka C. Regulation of GABA release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus. Brain Res. 761:1997;105-112.
93. 2A receptors. Eur. J. Pharmacol. 280:1995;R9-R11.
94. McGurk S.R., Meltzer H.Y. The role of cognition in vocational functioning in schizophrenia. Schizophr. Res. 45:2000;175-184.
95. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21(2S):1999;106S-115S.
96. Meltzer H.Y., Fatemi S.H. The role of serotonin in schizophrenia and the mechanism of action of anti-psychotic drugs. Kane J.M., Möller H.-J., Awouters F. Serotonergic Mechanisms in Antipsychotic Treatment. 1996;77-107 Marcel Dekker, New York.
97. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25:1999;233-256.
98. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 43(4):1991;587-604.
99. Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2:1976;19-76.
100. Meltzer H.Y., Young M., Metz J., Fang V.S., Schyve P.M., Arora R.C. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J. Neural Transm. 45:1979;165-175.
101. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
102. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry. 60:2003;82-91.
103. Meneses A. Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Rev. Neurosci. 9:1998;275-289.
104. 1A receptors. J. Pharmacol. Exp. Ther. 295:2000;853-861.
105. Millan M.J., Dekeyne A., Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology. 37(7):1998;953-955.
106. Millan M.J., Gobert A., Newman-Tancredi A., Audinot V., Lejeune F., Rivet J.M., Cussac D., Nicolas J.P., Muller O., Lavielle G. S16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1- (4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286:1998;1341-1355.
107. Millan M.J., Schreiber R., Dekeyne A., Rivet J.M., Bervoets K., Mavridis M., Sebban C., Maurel-Remy S., Newman-Tancredi A., Spedding M., Muller O., Lavielle G., Brocco M. S 16924((R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5- yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286:1998;1356-1373.
108. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54:1990;1755-1760.
109. 1A receptor agonist, in normal and p-chlorophenylalanine- treated rats as measured by in vivo microdialysis. Neurosci. Res. 31:1998;23-29.
110. 35S] GTPγS binding study. Eur. J. Pharmacol. 355:1998;245-256.
111. Nocjar C., Roth B.L., Pehek E.A. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience. 111(1):2002;163-176.
112. 2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double-blind PET study of schizophrenic patients. Biol. Psychiatry. 33:1993;227-235.
113. 2 receptor occupancy in olanzapine-treated patients. Arch. Gen. Psychiatry. 55:1998;283-284.
114. Nutt D.J. The neuropharmacology of serotonin and noradrenaline in depression. Int. Clin. Psychopharmacol. 17(Suppl. 1):2002;S1-S12.
115. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology. 110:1993;265-272.
116. 6 receptor gene and schizophrenia. Neurosci. Lett. 310:2001;17-20.
117. Oka M., Noda Y., Ochi Y., Furukawa K., Une T., Kurumiya S., Hino K., Karasawa T. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J. Pharmacol. Exp. Ther. 264:1993;158-165.
118. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 385:1997;634-636.
119. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., Toru M. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci. 66:2000;2455-2464.
120. Ostroff R.B., Nelson J.C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry. 60:1999;256-259.
121. Ozdemir V., Fourie J., Özdener F. Aripiprazole (Otsuka Pharmaceutical Co.). Curr. Opin. Invest. Drugs. 3:2002;113-120.
122. Pehek E.A., Yamamoto B.K. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J. Neurochem. 63:1994;2118-2124.
123. 2C receptors. Mol. Brain Res. 23:1994;163-178.
124. Prisco S., Pagannone S., Esposito E. Serotonin-dopamine interactions in the ventral tegmental area: an electrophysiological study in vivo. J. Pharmacol. Exp. Ther. 271:1994;83-90.
125. Purdon S.E. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. J. Psychiatry Neurosci. 25:2000;108-116.
126. Pycock C.J., Kerwin R.W., Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 286:1980;74-76.
127. Ranjan R., Meltzer H.Y. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol. Psychiatry. 40:1996;253-258.
128. Rasmussen K., Aghajanian G.K. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology. 1:1988;101-107.
129. 2C receptor antagonist. Br. J. Pharmacol. 126:1999;572-574.
130. Reynolds G.P. The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs. 51:1996;7-11.
131. Reynolds G.P., Zhang Z.-J., Zhang X.-B. Associations of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 359:2002;2086-2087.
132. Rinaldi-Carmona M., Congy C., Santucci V., Simiand J., Gautret B., Neliat G., Labeeuw B., Le Fur G., Soubrie P., Breliere J.C. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J. Pharmacol. Exp. Ther. 262:1992;759-768.
133. 6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology. 158:2001;114-119.
134. 1A receptor activation. Eur. J. Pharmacol. 338:1997;R3-R5.
135. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry. 48:2000;229-237.
136. 1C receptors. J. Pharmacol. Exp. Ther. 260:1992;1361-1365.
137. 7 receptors. J. Pharmacol. Exp. Ther. 268:1994;1403-1410.
138. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology. 120:1995;365-368.
139. Rowley H.L., Needham P.L., Kilpatrick I.C., Heal D.J. A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 361:2000;187-192.
140. 7) activating cAMP formation. Proc. Natl. Acad. Sci. USA. 90:1993;8547-8551.
141. Sakaue M., Somboonthum P., Nishihara B., Koyama Y., Hashimoto H., Baba A., Matsuda T. Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Brit. J. Pharmacol. 129:2000;1028-1034.
142. 1 receptor agonist. Eur. J. Pharmacol. 307:1996;27-31.
143. 1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 251:1991;947-950.
144. 2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum. Br. J. Pharmacol. 122:1997;520-524.
145. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
146. Seeman P., Van Tol H.H. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15:1994;264-270.
147. Seeman P., Chau-Wong M., Tedesco J., Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci. USA. 72:1975;4376-4380.
148. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
149. Sesack S.R., Bressler C.N., Lewis D.A. Ultrastructural associations between dopamine terminals and local circuit neurons in the monkey prefrontal cortex: a study of calretinin-immunoreactive cells. Neurosci. Lett. 200:1995;9-12.
150. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry. 158:2001;131-134.
151. 6 receptor gene in schizophrenia. Am. J. Med. Genet. 88:1999;120-122.
152. 6 receptor: localization and function. Ann. N. Y. Acad. Sci. 861:1998;91-96.
153. Sleight A.J., Boess F.G., Bös M., Levet-Trafit B., Riemer C., Bourson A. Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors. Br. J. Pharmacol. 124:1998;556-562.
154. Sokoloff P., Giros B., Martres M.P., Bouthenet M.-L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor D3 as a target for neuroleptiques. Nature. 347:1990;146-151.
155. 1A selective agonists. Eur. J. Pharmacol. 128:1986;295-298.
156. 1A receptor activation. Neuropsychopharmacology. 21:1999;622-631.
157. 123I]- Epidepride single photon emission tomography (SPET) study. Br. J. Psychiatry. 177:2000;408-415.
158. Sumiyoshi T., Matsui M., Nohara S., Yamashita I., Kurachi M., Sumiyoshi C., Jayathilake K., Meltzer H.Y. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry. 158:2001;1722-1725.
159. 1A agonist, on memory function in schizophrenia. Biol. Psychiatry. 49:2001;861-868.
160. 2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology. 148:2000;400-403.
161. Thase M.E. What role do atypical antipsychotic drugs have in treatment-resistant depression? J. Clin. Psychiatry. 63:2002;95-103.
162. 123I-5-I-R-91150. Br. J. Psychiatry. 173:1998;236-241.
163. VanderMaelen C.P., Braselton J.P. Effects of a potential antipsychotic, BMY 14802, on firing of central serotonergic and noradrenergic neurons in rats. Eur. J. Pharmacol. 179:1990;357-366.
164. VanderSpek S.C., Brownlee B.A., Nobrega J., McClelland R.A., Seeman P., Kapur S. Converting a typical antipsychotic into an atypical oOne - the critical role of D2. Schizophr. Res. 60:2003;117-118.
165. 7 receptors: current knowledge and future prospects. Trend Pharmacol. Sci. 21:2000;70-77.
166. 6) receptor gene in bipolar affective disorder and schizophrenia. Am. J. Med. Genet. 96:2000;217-221.
167. Volonté M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69:1997;182-190.
168. Wadenberg M.L., Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J. Neural Transm. 83(1-2):1991;43-53.
169. 2 receptor blocking agent, ritanserin, in the rat. Eur. Neuropsychopharmacol. 6:1996;305-310.
170. Wadenberg M.L., Hertel P., Fernholm R., Hygge Blakeman K., Ahlenius S., Svensson T.H. Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J. Neural Transm. 107(10):2000;1229-1238.
171. Westerink B.H., Kawahara Y., De Boer P., Geels C., De Vries J.B., Wikstrom H.V., Van Kalkeren A., Van Vliet B., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 412:2001;127-138.
172. Wettstein J.G., Host M., Hitchcock J.M. Selectivity of action of typical and atypical anti-psychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI). Prog. Neuro- psychopharmacol. Biol. Psychiatry. 23:1999;533-544.
173. Wiesel F.A., Nordstrom A.L., Farde L., Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology. 114:1994;31-38.
174. 1 receptors in prefrontal cortex. Nature. 376:1995;572-575.
175. Willins D.L., Deutch A.Y., Roth B.L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 27:1997;79-82.
176. 4 receptor involvement in the enhancement of acetylcholine release by p-chloroamphetamine in rat frontal cortex. Brain Res. 772:1997;95-101.
177. 4 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;712-720.
178. Yu Y.W., Tsai S.J., Lin C.H., Hsu C.P., Yang K.H., Hong C.J. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. NeuroReport. 10(6):1999;1231-1233.
179. 7 receptors in Hela cells. Neurosci. Lett. 288:2000;236-240.
180. Zimbroff D.L., Kane J.M., Tamminga C.A., Daniel D.G.M., Mack R.J.M., Wozniak P.J., Sebree T.B., Wallin B.A., Kashkin K.B. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am. J. Psychiatry. 154(6):1997;782-791.